Milgamma - a complex of vitamins of group B.
Release form and composition
- Solution for intramuscular injection (2 ml in ampoules of dark glass, 5 ampoules in blister packs, in a carton pack of 1, 2 or 5 packs; 5 ampoules in carton pallets, in a carton pack of 1 or 5 pallets; 10 ampoules in cardboard pallets, in a cardboard bundle 1 pallet);
- Dragee (15 pieces in blisters, in cardboard boxes 2 or 4 packs).
Active ingredients in 1 ml of solution:
- Pyridoxine hydrochloride (vitamin B 6 ) - 50 mg;
- Thiamine hydrochloride (vitamin B 1 ) - 50 mg;
- Lidocaine Hydrochloride - 10 mg;
- Cyanocobalamin (vitamin B 12 ) - 0.5 mg.
Active ingredients in 1 tablet:
- Pyridoxine hydrochloride - 100 mg;
- Benfotiamine (fat soluble form of thiamine) - 100 mg.
- Solution: sodium polyphosphate, sodium hydroxide, potassium hexacyanoferrate, benzyl alcohol, water injection;
- Dragees: aerosil, glycerides of fatty acids, sodium carboxymethylcellulose, sucrose, povidone, microcrystalline cellulose, corn starch, calcium carbonate, titanium dioxide, acacia powder, polyethylene glycol-6000, tween-80, glycerol, glycol wax, shellac, talc.
Indications for use
Milgamma is used as a symptomatic and pathogenetic agent in the complex therapy of the following syndromes and diseases of the nervous system:
- Neuritis, neuralgia;
- Retrobulbar neuritis;
- Paresis of the facial nerve;
- Ganglionites (including shingles);
- Polyneuropathy (diabetic and alcoholic);
- Neurological manifestations of spinal osteochondrosis: lumbar ischialgia, radiculopathy (radicular syndrome), musculo-tonic syndromes;
- Nighttime muscle cramps, especially in people of older age groups;
- Systemic neurological diseases caused by deficiency of vitamins B 1 and B 6 .
Milgamma use is strictly contraindicated in the following cases:
- Decompensated heart failure;
- Hypersensitivity to the drug.
Dosing and Administration
Milgamma solution is injected deep into the muscle.
In severe pain syndrome during the first 5-10 days, the drug is used daily at a dose of 2 ml. After improvement, the patient is transferred to the oral form of the drug (preferably). If this is not possible, reduce the frequency of injections to 2-3 times a week.
In the form of a dragee Milgamm appoint 1 pc. 3 times a day (with a sufficient amount of fluid). The duration of admission is usually 1 month.
In most cases, Milgamma is well tolerated. In rare cases, the following side effects occur:
- Allergic reactions: skin rash, urticaria, shortness of breath, angioedema, anaphylactic shock;
- Nervous system: confusion and dizziness;
- Cardiovascular system: tachycardia, arrhythmia, bradycardia;
- Digestive system: vomiting;
- Skin and subcutaneous tissues: itching, acne, increased sweating;
- Musculoskeletal system: convulsions;
- Local reactions: irritation at the injection site.
In case of overdose or rapid administration of the drug, systemic reactions are possible.
Milgamma solution is not allowed to be administered intravenously.
Information about the negative impact of the drug on the speed of psychophysical reactions and the ability to concentrate is absent.
Thiamine is destroyed in solutions containing sulfites, and its decomposition products inactivate the action of other vitamins.
Pyridoxine, taken in therapeutic doses simultaneously with levodopa, weakens its effect, i.e. reduces antiparkinsonian effect. The interaction with penicillamine, cycloserine, isoniazid is also noted.
Thiamine loses its effectiveness at a pH level of more than 3. Incompatible with reducing and oxidizing compounds, incl. benzylpenicillin, riboflavin, dextrose, tannin acid, phenobarbital, ammonium iron citrate, carbonates, disulfites, iodides, acetates. Its destruction accelerates copper.
Cyanocobalamin is incompatible with heavy metal salts.
Milgamma should be used with caution simultaneously with cycloserine and D-penicillamine.
Terms and conditions of storage
Keep out of the reach of children, protected from light.
- Solution - 2 years at a temperature up to 15 ºС;
- Dragee - 5 years at temperatures up to 25 ºС.